bims-ripira Biomed News
on RRM2B MDMD in Adults
Issue of 2026–05–03
thirteen papers selected by
Martín Lopo



  1. Front Neurosci. 2026 ;20 1775132
       Background: MSTO1 encodes a regulator of mitochondrial fusion. Mutations in MSTO1 are linked to a rare mitochondrial disorder characterized by early-onset myopathy and cerebellar ataxia, with 31 cases reported globally to date, which underscores its exceptional rarity.
    Methods: We conducted comprehensive clinical, molecular, and biochemical investigations in a patient harboring novel MSTO1 variants.
    Results: We identified a patient presenting with adult-onset progressive ataxia and cerebellar atrophy who carried two novel compound heterozygous variants in the MSTO1 gene (c.756A>G, p.Glu252Glu; c.1339G>A, p.Glu447Lys). Brain MRI revealed marked cerebellar abnormalities, but the patient's clinical symptoms remained relatively mild with preserved daily function. This milder phenotype, characterized by adult onset and later disease presentation, contrasts with the more severe neurological deficits reported in a previously described case. Functional studies revealed significantly reduced MSTO1 protein expression, mtDNA depletion, and impaired mitochondrial function, as reflected by decreased mitochondrial membrane potential and respiratory capacity, suggesting a pathogenic role for these variants. Comparative analysis with fibroblasts from a previously reported case with MSTO1 mutation revealed notable differences in the severity of mitochondrial dysfunction, suggesting potential genotype-phenotype correlations.
    Conclusion: Our findings provide evidence linking the novel MSTO1 variants c.756A>G and c.1339G>A to mitochondrial dysfunction and broaden the phenotypic spectrum of MSTO1-related mitochondrial disorders to encompass a milder, adult-onset form of cerebellar ataxia. These results emphasize the importance of integrated clinical and functional approaches in evaluating variant pathogenicity and in elucidating the clinical and molecular heterogeneity of MSTO1-related mitochondrial disorders.
    Keywords:  MSTO1; MSTO1-related mitochondrial disorders; cerebellar ataxia; cerebellar atrophy; mitochondrial fusion
    DOI:  https://doi.org/10.3389/fnins.2026.1775132
  2. NPJ Dement. 2026 ;2(1): 25
      Single large-scale mitochondrial DNA deletions (SLSMDs) are among the most common mitochondrial disorders. Adult-onset rapidly progressive dementia (RPD) due to an SLSMD has not previously been described. A 35-year-old male was referred to our clinic for assessment of RPD after developing rapidly progressive cognitive, behavioral, and motor symptoms over 14 months. Serial brain MRIs demonstrated progressive severe left temporal, moderate right temporal, and mild global brain parenchymal atrophy without T2-weighted or diffusion-weighted MRI abnormalities. Blood and cerebrospinal fluid testing showed elevated nonspecific markers of neurodegeneration (neurofilament light chain, 14-3-3γ, and neuron-specific enolase). After excluding common etiologies of RPD, mitochondrial genome sequencing revealed a novel de novo SLSMD (m.608_14511del). Brain magnetic resonance spectroscopy of the left thalamus demonstrated spectra suggestive of a lactate peak. This case demonstrates that SLSMDs can present with RPD as the primary clinical manifestation and should be considered in the differential diagnosis of RPD in young adults.
    Keywords:  Diseases; Neurology; Neuroscience
    DOI:  https://doi.org/10.1038/s44400-026-00081-z
  3. Front Sports Act Living. 2026 ;8 1710264
       Background: Mitochondrial myopathy (MM) is a group of rare, progressive muscle disorders characterized by impaired oxidative phosphorylation due to mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) mutations, leading to exercise intolerance, muscle weakness, and metabolic dysfunction. Although exercise is increasingly recognized for its capacity to enhance mitochondrial function and muscle performance, the specific effects of different exercise prescriptions (in terms of modality, intensity, and duration) on MM and their phenotype-specific outcomes remain heterogeneous. This study systematically investigates how various exercise types influence mitochondrial function, muscle performance, and clinical outcomes across MM subtypes.
    Methods: Databases including PubMed, Web of Science, Embase, and Scopus were searched from 1990 to September 2025. Clinical trials involving exercise interventions in MM patients were included, with outcomes covering exercise capacity, muscle function, mitochondrial markers, and metabolic indices. Risk of bias was assessed using Revised Cochrane Risk-of-Bias Tool for Randomized Trials (RoB 2) and Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I V2), and methodological quality was appraised with the Mixed Methods Appraisal Tool (MMAT).
    Results: Fifteen studies (1 randomized controlled trial and 14 non-randomized trials) including a total of 157 MM patients (sample size per study: 4-20) were analyzed. Moderate-intensity aerobic and resistance exercise consistently improved maximal oxygen uptake (VO2 max), maximal workload (W max), muscle strength, and mitochondrial enzyme activity, with no consistent group-level increases observed in creatine kinase (CK) levels or mtDNA mutation burden. Aerobic training enhanced oxidative capacity, phosphocreatine (PCr) recovery, and antioxidant defense, while resistance training improved muscle strength, satellite cell activation, and reduced cytochrome c oxidase (COX)-deficient fibers. Combined regimens yielded additive benefits. Most interventions lasted 8-14 weeks, 3-5 sessions per week. Phenotype-specific responses were evident: patients with large-scale deletions or m.3243A>G mutations showed favorable adaptation, whereas other point mutations or microdeletions displayed variable or adverse responses.
    Conclusion: Moderate-intensity, phenotype-specific exercise prescriptions, especially those integrating both aerobic and resistance components, may enhance mitochondrial and muscular function in patients with mitochondrial myopathy while reducing the likelihood of adverse effects. However, larger controlled trials are needed to confirm long-term efficacy and to clarify potential risk profiles.
    Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251145502, PROSPERO CRD420251145502.
    Keywords:  exercise intervention; exercise recommendations; mitochondrial function; mitochondrial myopathy; pathological mechanisms
    DOI:  https://doi.org/10.3389/fspor.2026.1710264
  4. Front Nutr. 2026 ;13 1754850
       Background: Fatigue during intensive exercise is closely associated with metabolic inefficiency and lactate accumulation. While Icariin, a natural flavonoid, has demonstrated potential in enhancing exercise performance, the precise cellular mechanisms governing its anti-fatigue effects remain incompletely elucidated.
    Methods: We employed an integrated approach combining in vivo exercise models in C57BL/6 mice with in vitro C2C12 myotube systems. Mice received Icariin supplementation (50 or 100 mg/kg) for 4 weeks before comprehensive physiological assessments. Cellular studies utilized caffeine stimulation, transcriptomic profiling, and metabolic analyses. Molecular mechanisms were investigated through western blotting, immunofluorescence, and genetic knockdown approaches.
    Results: Icariin supplementation dose-dependently enhanced exercise performance, evidenced by increased maximal oxygen consumption (VO2max) and prolonged exhaustive running time. This improvement was accompanied by reduced blood lactate accumulation, skeletal muscle hypertrophy, and a shift toward oxidative fiber types. In C2C12 myotubes, Icariin directly attenuated lactate production by suppressing LDH activity and reprogramming cellular metabolism toward oxidative phosphorylation. Transcriptomic analysis revealed significant enrichment of mitophagy pathways, which was validated by enhanced mitophagic flux and improved mitochondrial membrane potential. Mechanistically, we identified TFEB as the key transcriptional regulator mediating Icariin's effects, evidenced by its dephosphorylation, nuclear translocation, and transactivation of mitophagic genes. Crucially, TFEB knockdown completely abolished Icariin-induced mitophagy, metabolic improvements, and lactate reduction.
    Conclusion: Our findings establish a comprehensive mechanistic pathway wherein Icariin activates TFEB to drive mitophagic clearance of dysfunctional mitochondria, thereby optimizing mitochondrial function and shifting energy metabolism toward oxidative phosphorylation. This TFEB-mitophagy axis represents the core mechanism through which Icariin enhances exercise performance and metabolic efficiency, providing novel insights into its anti-fatigue properties and potential therapeutic applications.
    Keywords:  TFEB; anti-fatigue; icariin; lactate; mitophagy
    DOI:  https://doi.org/10.3389/fnut.2026.1754850
  5. Nat Commun. 2026 Apr 30.
      Mitochondrial dysfunction is widely implicated in human disease, yet whether it plays a causal role and why effects are tissue-specific remain unclear. Here, we analyse over 15,000 RNA-sequencing datasets from 49 tissue types integrated with germline genetic data to investigate the impact of mitochondrial DNA (mtDNA) transcription on disease risk. We identify 25 nuclear genetic variants associated with mtDNA transcript abundance, revealing gene- and tissue-specific regulatory architectures. We then develop tissue-specific genetic scores to predict mtDNA transcript levels and validate them in independent datasets. Applying these scores to 377,439 UK Biobank participants reveals significant associations between predicted mtDNA transcript abundance and multiple common diseases and quantitative traits, many showing marked tissue specificity, including associations with hypertension and Parkinson's disease in biologically relevant tissues. These findings provide genetic evidence that variation in mtDNA transcriptional processes contributes to complex disease biology and highlight mitochondrial RNA processing as a compelling therapeutic target.
    DOI:  https://doi.org/10.1038/s41467-026-72649-5
  6. JBMR Plus. 2026 May;10(5): ziag052
      Sarcopenia in older adults increases fall risk and frailty. Improving muscle mass and function enhances balance and supports basic activities of daily living. Leucine-enriched essential amino acid supplementation combined with resistance training has been shown to enhance muscle performance. The present study evaluated muscle performance outcomes after 6 mo of these treatments. In an open-label randomized controlled trial, 66 participants were randomized equally to control and intervention groups (n = 33 each). Both groups consumed daily leucine-enriched essential amino acid supplements after exercise. The intervention group performed resistance training, and the control group followed regular walking and strengthening exercises. Primary outcomes were appendicular skeletal muscle mass index (ASMI), gait speed, and hand grip strength. Safety was assessed by adverse event reporting and laboratory tests. The results of this study show no significant improvement in ASMI in either group after 6 mo. Both groups demonstrated significant gait speed improvements, with no between-group difference. Hand grip strength improved only in the non-dominant hand of the control group. No serious adverse events occurred, and kidney function remained stable. In conclusion, 6 mo of daily leucine-enriched essential amino acid supplementation combined with exercise did not increase ASMI among healthy older adults. Gait speed showed a positive association with supplementation and daily exercise regardless of regimen. Improvement in hand grip strength was observed only in the non-dominant hand, warranting further investigation to clarify the effect of supplementation combined with exercise. Additional clinical studies are required to establish the effectiveness of this regimen in preserving muscle mass and enhancing functional performance. Clinical trial registration: This study has been registered with the Thai Clinical Trials Registry (ID: TCTR20210824002).
    Keywords:  Sarcopenia; aged; body composition; dietary supplements; essential amino acids; frail elderly; leucine; randomized controlled trial; resistance training; walking speed
    DOI:  https://doi.org/10.1093/jbmrpl/ziag052
  7. Front Immunol. 2026 ;17 1774310
      Post-exertional malaise (PEM) is a common core symptom in various chronic debilitating conditions, such as Post COVID-19 Condition (PCC, also known as Long COVID) and Chronic Fatigue Syndrome (CFS). It is characterized by the delayed and persistent exacerbation of symptoms following even mild physical or cognitive activities. This review presents a systematic review of the pathophysiological mechanisms involved in PEM, proposing a dynamic framework of multi-system interactions that may lead to homeostatic imbalance. The etiology of PEM is multifactorial, potentially involving factors such as the persistent presence of pathogens, exposure to environmental toxins, and genetic predisposition. Collectively, these factors may establish a vulnerable baseline that heightens the body's physiological response to stressors, such as exercise, potentially triggering a pathological reaction. First, mitochondrial dysfunction and metabolic abnormalities may act as potential initiating factors in PEM, manifesting as impaired ATP synthesis, overproduction of reactive oxygen species (ROS), and the accumulation of metabolic byproducts. It is crucial to emphasize that exercise itself induces a 'toxic excitatory effect,' whereby healthy individuals enhance mitochondrial function and antioxidant defenses through physical activity. However, in individuals predisposed to PEM, due to underlying pathological conditions (e.g., sequelae of viral infections), this adaptive process is disrupted, preventing effective restoration of mitochondrial homeostasis and may initiate a potential vicious cycle of dysfunction. Second, ROS and mitochondrial DNA (mtDNA), as damage-associated molecular patterns (DAMPs), along with pathogen-associated molecular patterns (PAMPs), may activate the NLRP3 inflammasome and induce the release of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, potentially transforming localized metabolic stress into a systemic inflammatory response. Subsequently, peripheral inflammation may be transmitted to the central nervous system through disruption of the blood-brain barrier and vagal nerve pathways, activating glial cells and initiating neuroinflammation. This process may ultimately affect the brain's interoceptive network, particularly the insular cortex, resulting in altered perception and processing of signals related to fatigue and pain. Furthermore, mitochondrial dysfunction in neurons may contribute to central energy depletion, which may impair synaptic plasticity and induce cognitive deficits and brain fatigue. Ultimately, this review proposes that PEM may arise from a complex interplay among mitochondrial dysfunction, immune activation, and neuroinflammation, which together form a self-perpetuating loop of "energy exhaustion - inflammation amplification," potentially contributing to the chronic and multi-system nature of PEM symptoms. The integrated "metabolism-immune-neuro" interaction model presented in this article may provide a potential comprehensive framework for understanding PEM and highlights the need for a multi-target, collaborative intervention approach that may help disrupt the pathological cycle.
    Keywords:  Post COVID-19 condition; chronic fatigue syndrome; energy metabolism; immunity; inflammation; mitochondrial dysfunction; neuroinflammation; post-exertional malaise
    DOI:  https://doi.org/10.3389/fimmu.2026.1774310
  8. PLoS One. 2026 ;21(4): e0347781
      Mitochondrial quality control is a crucial factor governing self-renewal capacity, maintenance of metabolic balance, and cellular longevity in stem cells. Impaired mitophagy significantly contributes to cellular senescence, causing accumulation of damaged mitochondria and impaired proliferative capacity of cells, leading to reduced therapeutic efficiency. This study explores mitophagy's role in regulating senescence in human adipose-derived mesenchymal stem cells (HADMSCs) and evaluates the therapeutic potentiality of antioxidants-melatonin and coenzyme Q10 (CoQ10) targeting mitochondria. It also examines the impact of antioxidant intervention aimed at improving the fate and survival, thereby establishing a connection between metabolic reprogramming and mitophagy. Our study found that stress-induced HADMSCs have reduced Mitochondrial Membrane potential (MMP), increased ROS, and increased senescence-associated β-galactosidase activity as observed through fluorescence-based imaging and biochemical assays. It was observed that antioxidant intervention has prevented the damage caused by the stress and reduced mitochondrial ROS and lipid peroxidation and has significantly restored mitophagy markers like Parkin, NDP52, BNIP3, BNIP3L/Nix, and LC3B. Our findings suggest that antioxidants induced pharmacological stimulation of mitophagy could potentially reverse stem cell aging and prevent functional decline, thereby improving regeneration and offering new insights and perspectives on mitochondrial health for improved efficiency of stem cell transplantation, maintenance and longevity of HADMSCs.
    DOI:  https://doi.org/10.1371/journal.pone.0347781
  9. Neurol Int. 2026 Mar 26. pii: 64. [Epub ahead of print]18(4):
       BACKGROUND: Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis, represent a major global health burden and share convergent pathogenic mechanisms, such as mitochondrial dysfunction, oxidative stress, neuroinflammation, calcium imbalance, and neuronal loss. Despite advances in symptomatic management, effective disease-modifying therapies remain limited.
    OBJECTIVES: This review aims to critically synthesize mechanistic, preclinical, and clinical evidence on α-lipoic acid and biotin as candidate neuroprotective agents in neurodegenerative diseases, with emphasis on shared signaling pathways, therapeutic potential, generally favorable safety profiles, and translational limitations.
    METHODS: A narrative and integrative review was conducted, encompassing mechanistic studies, preclinical experimental models, and clinical trials and observational studies evaluating ALA and biotin in neurodegenerative diseases. The evidence was qualitatively analyzed with attention to biological plausibility, consistency across models, and clinical relevance.
    RESULTS: ALA and biotin modulate key cellular pathways implicated in neurodegeneration, including mitochondrial metabolism, redox homeostasis, inflammatory signaling, and neurovascular function. Preclinical studies consistently report beneficial effects on mitochondrial efficiency, oxidative stress, and neuroinflammatory markers. In contrast, clinical evidence remains heterogeneous, with more extensive evaluation of biotin in progressive multiple sclerosis and more limited or exploratory findings for ALA across neurodegenerative disorders.
    CONCLUSIONS: ALA and biotin exhibit mechanistic convergence across pathways relevant to neurodegeneration and generally favorable safety profiles. Although current evidence supports their biological plausibility as adjunctive or exploratory therapeutic strategies, clinical outcomes remain inconsistent and appear to be influenced by dosing regimens, disease stage at intervention, and endpoint selection. Well-designed clinical studies are required to define their efficacy, optimal dosing, and disease-specific applicability.
    Keywords:  biotin; neurodegenerative disease; α-lipoic acid
    DOI:  https://doi.org/10.3390/neurolint18040064
  10. Front Pharmacol. 2026 ;17 1783888
      Autism spectrum disorder (ASD) is a group of neurodevelopmental disorders characterized by social communication deficits, restricted and fixated interests and abnormal motor behaviors. Increasing evidence implicates oxidative stress, mitochondrial dysfunction, and neuroinflammation as key biological features of ASD. Aberrant redox homeostasis, reduced glutathione reserves, increased lipid peroxidation, and dysregulated NRF2 signaling have been documented in both peripheral tissues and brain samples. Post-mortem and imaging studies further reveal deficits in electron transport chain complexes and pyruvate dehydrogenase activity, suggesting a mechanistic link between mitochondrial bioenergetics and ASD-related phenotypes. These pathomechanisms have motivated interest in antioxidant metabolites from botanical drugs and nutrients as complementary strategies. To critically appraise mechanisms and levels of evidence (in vitro, in vivo, clinical) for vitamin E and C, glutathione and its precursors, polyphenols (quercetin, resveratrol, curcumin), Crocus sativus carotenoids (crocin/safranal), and "indirect" modulators (e.g., omega-3, folinic acid), emphasizing study quality, translational relevance, and limitations. The aim of this review is to synthesize current findings on the potential benefits of antioxidants in addressing both molecular and behavioral aspects of ASD, while also examining the link between oxidative stress and ASD. Furthermore, we discuss the role of antioxidant-based interventions in managing ASD symptoms. The review highlights the complex challenges associated with antioxidant therapies and deficiencies, emphasizing the need for a multifaceted nutritional approach particularly in children with ASD.
    Keywords:  autism; crocin; curcumin; electron transport chain; quercetin; resveratrol; safranal; vitamins
    DOI:  https://doi.org/10.3389/fphar.2026.1783888
  11. Cell Commun Signal. 2026 May 01.
      Mitochondrial dysfunction resulting in mitochondrial DNA (mtDNA) leakage is one of the main triggers of immune responses in systemic lupus erythematosus (SLE). In contrast, mitochondrial RNA (mtRNA) leakage and its role in SLE remains poorly understood. Interferon-alpha (IFN-α) and immune complexes (ICs) are both pathogenic contributors to SLE. Following the detection of increased mtRNA in the serum of patients with SLE, we explored the mechanisms of mtRNA leakage. Exposure to IFN-α at 100 U/ml, a pathophysiological concentration detected in SLE patients with mild to moderate disease activity, resulted in mitochondrial permeability transition pore (mPTP) opening and voltage dependent anion channel 1 (VDAC1) oligomerization, leading to mtRNA leakage and downstream inflammatory pathway activation in bone marrow-derived macrophages (BMDMs) of mice. However, we did not observe the activation of BCL2 antagonist/killer 1 (BAK) and BAK/BCL2-associated X (BAX) (BAX/BAK) pores and mitophagy does not play roles in these effects. Overloaded mitochondrial calcium released from the endoplasmic reticulum is likely responsible for mitochondrial pore opening. Similar effects were observed with ICs treatment. Several commonly recognized events contributing to mitochondrial pore opening such as cell death, apoptosis and changes of mitochondrial membrane potential were not detected and a pan-caspase inhibitor Z-VAD-FMK could not block IFN-α and ICs-induced mtRNA release. Our studies demonstrated an unexpected phenomenon that a pathophysiological concentration of IFN-α and ICs can selectively induce mitochondrial pore opening leading to mtRNA release in primary macrophages.
    Keywords:  Interferon-alpha; Macrophages; Mitochondria; Mitochondrial RNA; Mitochondrial pore; Systemic lupus erythematosus
    DOI:  https://doi.org/10.1186/s12964-026-02910-3
  12. Nucleic Acids Res. 2026 Apr 23. pii: gkag233. [Epub ahead of print]54(8):
      Mitochondrial DNA replication occurs at contact sites between the endoplasmic reticulum (ER) and mitochondria (ERMCS). Beyond the known role of the tubular ER protein RTN4, the factors regulating this process are poorly defined. Here, we show that repressing the ER protein ERLIN2 in human fibroblasts depletes ER-mitochondrial contact sites and inhibits mitochondrial DNA replication, as does silencing RTN4 or the ER-mitochondrial tether GRP75. GRP75 or RTN4 scarcity also decreases the level of the mitochondrial calcium uniporter (MCU), whose inhibition blocks mitochondrial DNA synthesis. Because ERMCS depletion did not diminish mitochondrial calcium, and MCU complex can transport manganese, we tested whether manganese could bypass these defects. Manganese supplementation restored mitochondrial DNA replication in cells lacking ERMCS or with inhibited MCU, identifying manganese as a critical mediator. We then considered mitochondrial transcription as a potential manganese target, since it provides both transcripts for gene expression and primers for DNA replication. In vitro, manganese inhibits transcription re-start and stimulates RNA synthesis at the light-strand origin of replication. These findings support a model in which ER-mitochondrial contact sites, in conjunction with MCU, deliver manganese from the ER to mitochondria to promote DNA replication, potentially by modulating mitochondrial RNA polymerase activity.
    DOI:  https://doi.org/10.1093/nar/gkag233
  13. Front Aging Neurosci. 2026 ;18 1778574
       Background: Chronic kidney disease (CKD) and cognitive frailty frequently co-occur in older adults, compounding adverse health outcomes and placing substantial strain on healthcare systems.
    Summary: This review outlines the molecular pathways that link CKD to cognitive decline, including chronic inflammation, oxidative stress, vascular dysfunction, hormonal dysregulation, and interactions along the gut-kidney-brain axis. Recent advances in neuroimaging offer objective biomarkers of brain atrophy, white matter injury, and disrupted functional connectivity.
    Key messages: Multi-omics and single-cell technologies are uncovering cell-type-specific mechanisms and candidate biomarkers, paving the way for precision medicine approaches. Emerging strategies include integrated geriatric-nephrology care models and targeted interventions, such as SGLT2 inhibitors, IL-6 antagonists, microbiome modulation, and structured exercise programs. Bioengineering and artificial intelligence now enable the integration of multimodal data to support risk prediction, disease monitoring, and individualized therapeutic planning. Future priorities should focus on longitudinal cohort studies, interventional trials with cognitive endpoints, and the development of rigorously validated AI-driven predictive models. Effectively addressing CKD-related cognitive frailty will require translating molecular insights into clinical practice to mitigate vulnerability in aging populations.
    Keywords:  artificial intelligence; chronic kidney disease; cognitive frailty; gut–kidney–brain axis; multi-omics; neuroimaging
    DOI:  https://doi.org/10.3389/fnagi.2026.1778574